<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00538811</url>
  </required_header>
  <id_info>
    <org_study_id>648-Med</org_study_id>
    <nct_id>NCT00538811</nct_id>
  </id_info>
  <brief_title>Interferon-gamma With Interferon Alpha and Ribavirin for Hepatitis C Non-responders</brief_title>
  <official_title>Interferon-gamma With Interferon Alpha and Ribavirin for Hepatitis C Patients Who Are Non-responders to Interferon Alpha Plus Ribavirin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aga Khan University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Aga Khan University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      When administered simultaneously, interferon-alpha 2b + interferon-gamma result in dramatic
      antiviral synergy.Ribavirin has shown to enhance interferon-gamma levels in patients with
      chronic hepatitis C treated with interferon-alpha. Enhancement of immune responses,
      especially those related to type-1 T helper cell activity, may contribute to better efficacy
      in combining ribavirin with IFN-alpha for treatment of chronic hepatitis C. The aim of the
      present study is to evaluate the efficacy and safety of a triple regimen, a combination
      treatment with Interferon gamma, Interferon alfa-2b plus Ribavirin in patients who have not
      previously responded to interferon alpha in combination of ribavirin.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Hepatitis C</condition>
  <condition>Genotype 3</condition>
  <condition>Non-responders</condition>
  <condition>Relapsers</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Interferon alpha, ribavirin, interferon gamma</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Interferon alpha, ribavirin, amantadine</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>interferon alpha-2b, ribavirin, interferon-gamma,</intervention_name>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>interferon alpha-2b, ribavirin, amantadine</intervention_name>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Non-responders and relapsers to previous interferon and ribavirin therapy given for
             six months

          -  HCV genotype 3

          -  Compensated liver disease

          -  Hb ≥10 g/dl (females),≥11 g/dl (males)

          -  Platelets count ≥ 100,000 / cubic mm

          -  Neutrophils count ≥1,500/cubic mm

          -  ≥18 years to ≤ 70 years.

          -  At least one abnormal ALT value in the last year.

          -  TSH level within normal limits.

          -  Non pregnant adult females.

          -  Absence of drug or alcohol abuse.

          -  Informed consent given by the patient

        Exclusion Criteria:

          -  Patient younger than 18 yrs and older than 70 yrs.

          -  Hepatitis B or HIV co-infection.

          -  Severe renal dysfunction or creatinine clearance less than 50 ml/min

          -  Pregnant women or breast feeding women.

          -  Suspected hypersensitivity to Interferon alpha, gamma or ribavirin.

          -  Decompensated liver cirrhosis.

          -  History or any other evidence of other causes of CLD other than hepatitis C infection
             ( like hemochromatosis,, autoimmune hepatitis, metabolic liver disease, alcoholic
             liver disease, toxin exposure, Wilson's disease,Drug induced liver disease)

          -  Active malignant disease.

          -  Any known pre-existing medical condition that could interfere with subject's
             participation or completion of study such as psychiatric condition, seizures disorder
             requiring medications, co existing heart diseases, lung diseases, poorly controlled
             diabetes, auto immune diseases, gout)

          -  History of interferon and/or ribavirin intolerance
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zaigham Abbas, FCPS, FACG</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Aga Khan University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medicare Clinic</name>
      <address>
        <city>Karachi</city>
        <zip>74800</zip>
        <country>Pakistan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Aga Khan University Hospital</name>
      <address>
        <city>Karachi</city>
        <zip>74800</zip>
        <country>Pakistan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Pakistan</country>
  </location_countries>
  <verification_date>October 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 2, 2007</study_first_submitted>
  <study_first_submitted_qc>October 2, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 3, 2007</study_first_posted>
  <last_update_submitted>October 26, 2010</last_update_submitted>
  <last_update_submitted_qc>October 26, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 27, 2010</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Ribavirin</mesh_term>
    <mesh_term>Interferon-alpha</mesh_term>
    <mesh_term>Interferon-gamma</mesh_term>
    <mesh_term>Amantadine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

